SHH Culture Medium for Neuromuscular Organoid Maturation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for culturing neuromuscular organoids are limited in their ability to reproduce the inherent properties and characteristics of tissues, particularly in differentiating motor neurons and skeletal muscle tissues, and are not suitable for large-scale drug screening, which is crucial for studying degenerative neuromuscular diseases.

Innovation Solution

A medium composition for culturing neuromuscular organoids is developed, containing a sonic hedgehog (SHH) signaling activator, which promotes the differentiation of pluripotent stem cells into bipotent neuromesodermal progenitors, followed by embryoid body formation and culturing in a medium with an SHH signaling activator to create a three-dimensional neuromuscular organoid.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional two-dimensional cell culture methods are used, then the culture process is simple and easy to perform, but the ability to reproduce inherent properties and characteristics of tissues is poor

Engineering Contradiction:
Improveability to reproduce tissue propertiesVSAvoidculture method complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent transitions from conventional two-dimensional cell culture to three-dimensional organoid culture. This dimensional change enables the cells to self-organize into structures that better replicate in vivo tissue architecture and cellular interactions, thereby improving the reliability of tissue property reproduction while accepting increased cultural complexity

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

2Adaptability or versatility

If xenograft models are used, then alternative to animal testing is provided, but large-scale drug screening is not suitable

Engineering Contradiction:
Improvedrug screening applicabilityVSAvoidmodel production complexity
Core Design Contradiction:
Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent creates simplified copies of neuromuscular tissue through organoid culture from stem cells. These organoid models replicate the essential functional characteristics of native tissue but in a more controllable and scalable format, enabling large-scale drug screening while reducing manufacturing complexity compared to xenograft models

Inventive Principle:
Principle #26Copying

3Manufacturing precision

If existing neuromuscular organoid methods are used, then basic research is enabled, but motor neuron differentiation efficiency is low (only 6%)

Engineering Contradiction:
Improvemotor neuron differentiation efficiencyVSAvoidculture medium composition
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent optimizes the culture medium composition by adjusting concentrations of specific factors including SHH signaling activators, growth factors, and small molecules. These parameter changes in the chemical environment of the culture system significantly improve motor neuron differentiation efficiency from 6% to over 80%, while maintaining a manageable culture system complexity

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP4711447A1Medium composition for culturing neuromuscular organoid and method for producing neuromuscular organoid
Publication Date: 2026.03.18 ANIMUSCURE INC
  • EP4711447A1 patent drawingFigure 1
  • EP4711447A1 patent drawingFigure 2
  • EP4711447A1 patent drawingFigure 3A

AI summary

The present disclosure relates to a medium composition for culturing a neuromuscular organoid, a manufacturing method for a neuromuscular organoid, etc. The neuromuscular organoid of the present disclosure is cultured in a medium containing a composition including a sonic hedgehog signaling agonist as an active ingredient, thereby promoting not only a process of differentiating neurons constituting the neuromuscular organoid into motor neurons, but also development and maturation of muscle fibers. The interactions between motor neurons and muscle tissues through a neuromuscular junction are essential for the cause and treatment of degenerative neuromuscular diseases, and thus, the neuromuscular organoid of the present disclosure can be used as a model of neuromuscular diseases (specifically, a degenerative neuromuscular disease model). Therefore, the present disclosure is expected to be applicable even to research on the mechanism of neurological and muscular diseases and to drug screening.